Drug Addiction Treatment Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

The Drug Addiction Treatment Market Report is Segmented by Treatment Type (Medication-Assisted Treatment (MAT), Behavioral Therapy, and More), Addiction Type (Opioid Addiction, and More), Age Group (Adolescents (12-17 Years), and More), Treatment Setting (Inpatient Treatment Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Size and Forecasts are Provided in Terms of Value (USD).

Drug Addiction Treatment Market Size and Share

Drug Addiction Treatment Market Size
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Drug Addiction Treatment Market Analysis by Mordor Intelligence

The Drug Addiction Treatment Market size is projected to expand from USD 16.98 billion in 2026 and USD 17.96 billion in 2027 to USD 25.29 billion by 2032, registering a CAGR of 7.09% between 2027 and 2032.

The drug addiction treatment market is moving from short, crisis-led episodes of care toward longer treatment pathways that combine medication, counseling, telehealth, and community services. In the United States, 44.6 million people aged 12 or older had a substance use disorder in 2025, including 26.0 million with a drug use disorder and 4.0 million with opioid use disorder. Of the 47.2 million people who needed substance use disorder treatment in 2025, 7.6 million received it, leaving a major treatment gap that supports demand for broader care delivery capacity. The drug addiction treatment market is also being shaped by permanent telehealth prescribing rules, growing demand for behavioral care for stimulant use disorder, and the expansion of long-acting medicines. Funding pressure on safety-net providers remains a material risk, particularly where treatment systems depend on public grants.

Key Report Takeaways

  • By treatment type, medication-assisted treatment held 33.21% of the drug addiction treatment market share in 2026, while behavioral therapy is forecast to grow at an 8.16% CAGR through 2032.
  • By addiction type, opioid addiction accounted for 36.01% of the drug addiction treatment market size in 2026, while stimulant addiction is forecast to expand at a 7.87% CAGR through 2032.
  • By age group, adults (18-64 years) held 71.25% revenue share in 2026, while adolescents aged 12 to 17 are forecast to grow at an 7.98% CAGR through 2032.
  • By treatment setting, outpatient treatment centers held 44.56% revenue share in 2026 and are forecast to grow at an 8.23% CAGR through 2032.
  • By geography, North America held 41.04% revenue share in 2026, while Asia-Pacific is forecast to grow at an 8.02% CAGR through 2032.

Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.

Drug Addiction Treatment Market Segment Analysis

By Treatment Type:

Medication-Assisted Treatment Holds the Largest Position While Behavioral Therapy Grows Faster

Medication-assisted treatment held 33.21% of revenue in 2026, making it the largest treatment type in the drug addiction treatment market. Its position reflects established use of buprenorphine, methadone, and naltrexone for opioid and alcohol use disorders. Permanent telehealth prescribing rules can extend the reach of buprenorphine treatment without requiring the same level of facility expansion. Behavioral therapy is forecast to grow at an 8.16% CAGR through 2032, the fastest rate among treatment types. This growth is closely linked to stimulant use disorder, where behavioral interventions remain central because no approved pharmacotherapy is available. Contingency management and cognitive-behavioral therapy have a defined evidence base for cocaine and methamphetamine use disorders.

Counseling and support programs connect the broader care pathway through group support, peer coaching, and 12-step facilitation. These services can provide ongoing recovery support at a lower cost per patient than higher-acuity clinical settings. Detoxification remains an important entry point for medically supervised withdrawal, especially where opioid or alcohol withdrawal creates immediate safety concerns. Rehabilitation programs, including inpatient and residential care, serve patients with more severe clinical and social needs. These programs can receive higher revenue per treatment episode because they combine accommodation, clinical care, and support for co-occurring psychiatric conditions. Accreditation and quality requirements remain important for payer contracting across the drug addiction treatment industry.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Drug Addiction Treatment Market Share by Treatment Type, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Drug Addiction Treatment Market Share by Treatment Type, 2026

By Addiction Type:

Opioid Treatment Maintains the Largest Base While Stimulant Care Gains Demand

Opioid addiction accounted for 36.01% of the drug addiction treatment market share in 2026, supported by a large network of methadone clinics, buprenorphine prescribers, and naltrexone programs. The segment reflects many years of policy focus on opioid-related harms and medication access. Yet 623,000 of the 4.0 million Americans with opioid use disorder received medication for opioid use disorder in 2025. This gap shows that the existing treatment base does not meet the full level of clinical need. Stimulant addiction is forecast to grow at a 7.87% CAGR through 2032, the highest rate among addiction types. The increase in cocaine and methamphetamine detection during 2026 points to a caseload that will require a larger behavioral treatment workforce.

Cannabis treatment demand rises as access expands and problematic use becomes more visible among people with a predisposition to dependence. Prescription drug addiction and tobacco or nicotine addiction have established treatment options, including varenicline and nicotine replacement therapy for smoking cessation. Other substance categories include hallucinogens, inhalants, ketamine, and club drugs. These categories have a smaller current base but are receiving research attention as treatment approaches progress through clinical development. In August 2025, UNODC brought together Cambodia, China, Lao PDR, Myanmar, Thailand, and Viet Nam to address treatment for stimulant use disorders and community-based psychosocial support. The drug addiction treatment market will therefore require care pathways that respond to local drug supply conditions as well as established opioid treatment needs.

By Age Group:

Adults Sustain Current Volume While Youth Care Becomes More Formalized

Adults aged 18 to 64 represented 71.25% of revenue in 2026, making them the core age group in the drug addiction treatment market. This position reflects the established medication treatment network, employer-supported behavioral health benefits, and Medicaid coverage available to working-age adults. Adults also make up a large share of people receiving formal services for opioid, alcohol, cannabis, and stimulant use disorders. Adolescents aged 12 to 17 are forecast to grow at 7.98% CAGR through 2032. In March 2026, ASAM and the Hazelden Betty Ford Foundation released the Adolescents and Transition-Aged Youth volume of The ASAM Criteria, the first dedicated clinical framework for youth substance use disorder care. The framework calls for developmentally appropriate assessment, family engagement, early intervention, and repeated review during care.

In 2025, 7.8% of adolescents aged 12 to 17 met substance use disorder criteria, while only 1 in 3 received outpatient treatment. Youth-focused clinical standards can help providers define services that qualify for dedicated reimbursement and improve referral practices. School-linked telehealth services and mobile crisis platforms may help programs reach adolescents before substance use causes more serious harm. These routes are particularly relevant for cannabis and stimulant use disorders, where exposure to fentanyl contamination can increase risk. The older population remains a smaller part of treatment demand, but polysubstance use involving opioids and benzodiazepines can create complex treatment needs. The drug addiction treatment industry must therefore maintain distinct clinical approaches for adolescents, adults, and older patients.

Segment this market the way your business does.

Get tailored market insights for your requirements.

Drug Addiction Treatment Market Share by Age Group, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Drug Addiction Treatment Market Share by Age Group, 2026

By Treatment Setting:

Outpatient Centers Lead Revenue and Growth

Outpatient treatment centers held 44.56% of revenue in 2026 and are forecast to grow at an 8.23% CAGR through 2032. This makes outpatient care both the largest and the fastest-growing setting in the drug addiction treatment market. Payers and public systems are favoring care models that can manage treatment episodes at a lower cost than residential or inpatient settings. Telehealth also allows outpatient programs to offer hybrid care that combines virtual medication visits with in-person testing, counseling, and referral services. Acadia Healthcare reported that it operated 178 comprehensive treatment centers serving 76,000 patients daily in 2025 and added 15 centers during the year. This footprint illustrates how outpatient networks can support treatment access at scale.

Residential rehabilitation remains important for people with co-occurring psychiatric conditions, severe social instability, or care needs that cannot be managed safely in an outpatient setting. Inpatient centers provide medical supervision during detoxification and acute stabilization, particularly for opioid and alcohol withdrawal. These settings require more intensive staffing and around-the-clock care. They also remain necessary when a patient’s medical, psychiatric, or housing conditions make routine outpatient attendance impractical. The drug addiction treatment market is not shifting entirely away from facility-based care because care intensity must match clinical need. Provider economics can differ sharply across settings because reimbursement, labor costs, and payer mix vary across outpatient, inpatient, and residential services.

Geography Analysis

North America

North America held 41.04% of revenue in 2026 and remained the largest regional base in the drug addiction treatment market. The United States accounts for much of this position through Medicaid, Medicare, private insurance, state block grants, and a large opioid treatment program network. The permanent telehealth rule can extend buprenorphine access into rural counties and populations with historically lower access to formal treatment. Canada has expanded supervised consumption and regulated drug supply pilots as part of its opioid response. Mexico has a less developed formal treatment system relative to its polysubstance use burden, which supports demand for community-based care investment.

Europe

Europe has state-funded substance use disorder networks in Germany, the United Kingdom, and France. The European Medicines Agency framework governs approval of new addiction medicines, including long-acting injectable options. The United Kingdom continues to invest in substance use treatment capacity through the National Health Service's long-term planning process. Scotland’s high drug mortality has increased pressure for rapid-access treatment services. Spain and Italy have expanded naloxone distribution and drug checking services that can provide lower-barrier entry into formal treatment. These services can connect people to counseling, medication, and continuing recovery support.

Asia-Pacific, Middle East and Africa, South America

Asia-Pacific is forecast to grow at an 8.02% CAGR through 2032, making it the fastest-growing geography in the drug addiction treatment market. UNODC reported that more than half of the world’s estimated opioid users live in Asia, equal to 1.2% of the regional population. Thailand is expanding community treatment and harm-reduction services through its Local Health Fund, while Malaysia broadened the scope of rehabilitation services in 2025. Myanmar’s illicit opium production and methamphetamine supply affect treatment demand across the Mekong subregion. India and China have large, undercounted populations with substance use disorder and are expanding public mental health frameworks. Middle East and Africa and South America remain smaller markets, although private healthcare growth in the Gulf and public health programs in Brazil and Argentina support selective treatment demand.

Drug Addiction Treatment Market Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market Concentration

Drug Addiction Treatment Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

The drug addiction treatment market is moderately fragmented across pharmaceutical manufacturers, treatment providers, generic drug companies, and behavioral health specialists. Indivior has focused its strategy on the SUBLOCADE franchise after discontinuing INDV-2000 following a Phase 2 failure and returning INDV-6001 rights to Alar Pharmaceuticals in April 2026. The company also presented real-world SUBLOCADE data at the ASAM 2026 Annual Conference and continues to support awareness of long-acting treatment. These actions show a focus on reinforcing an established injectable product rather than broadening an early-stage pipeline.

Competition in long-acting buprenorphine includes Brixadi, which offers weekly and monthly injectable doses. December 2025 Brixadi prescribing information update reflects continued regulatory development in this treatment area. Teva, Hikma, Sandoz, Viatris, Cipla, and Dr. Reddy’s Laboratories compete in buprenorphine and naloxone products, where price is a key competitive factor. Generic competition can limit the pricing flexibility of branded medication-assisted treatment products. Product differentiation is therefore linked to dosing convenience, clinical evidence, payer access, and provider confidence. The drug addiction treatment market also includes opportunities for companies that can support medication adherence and integrate behavioral care with pharmacotherapy.

Among providers, Acadia Healthcare is expanding capacity and working with health systems to support referral networks. Acadia reported plans in 2026 to add 600 beds by year-end and to realize a USD 200 million embedded EBITDA opportunity from beds added during the prior 3 years. Its joint venture approach with health systems can reduce capital needs and support patient referral flows. The divestiture of Recovery Brands by American Addiction Centers in 2025 separated digital care navigation assets from direct clinical delivery. This transaction shows that digital lead generation and clinical care delivery can operate as separate business models. The drug addiction treatment market has room for adolescent outpatient care, behavioral therapy for stimulant use disorder, and opioid treatment programs that combine remote prescribing with structured monitoring.

Drug Addiction Treatment Industry Leaders

  1. Alkermes plc

  2. Camurus AB

  3. Hikma Pharmaceuticals

  4. Indivior PLC

  5. Viatris Inc.

  6. *Disclaimer: Major Players sorted in no particular order

Drug Addiction Treatment Market Companies Covered in this Report

  • Acadia Healthcare Company, Inc.
  • Alkermes plc
  • American Addiction Centers
  • BayMark Health Services
  • BHG Holdings, LLC
  • Braeburn Inc.
  • Camurus AB
  • Cipla
  • Crossroads Treatment Centers
  • Ethypharm
  • Hazelden Betty Ford Foundation
  • Hikma Pharmaceuticals
  • Indivior
  • Orexo
  • Pinnacle Treatment Centers
  • Recovery Centers of America
  • Rusan Pharma
  • Teva Pharmaceutical Industries
  • Titan Pharmaceuticals, Inc.
  • Viatris

Recent Industry Developments in Drug Addiction Treatment Market

  • April 2026: Indivior presented real-world evidence at the ASAM 2026 Annual Conference in San Diego, demonstrating SUBLOCADE’s effectiveness in supporting remission and reducing overdose-related outcomes, reinforcing monthly injectable buprenorphine as a standard-of-care option.
  • December 2025: Indivior published randomized trial results reporting that SUBLOCADE 100-mg and 300-mg doses reduced opioid use from more than 43 instances per week at baseline to fewer than 3 by week 3, with results maintained through week 38.
  • October 2025: Indivior launched the nationwide “Move Forward in Recovery” campaign to raise awareness of SUBLOCADE and long-acting injectables for moderate-to-severe opioid use disorder.

Table of Contents for Drug Addiction Treatment Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Substance Use Disorder Prevalence and Overdose Burden
    • 4.2.2 Growing Awareness and Acceptance of Addiction Treatment
    • 4.2.3 Public Funding and Insurance Parity Expansion
    • 4.2.4 Telehealth and Digital Therapeutics Extending Treatment Access
    • 4.2.5 Harm-Reduction and Community-Based Care Expansion
    • 4.2.6 Rapid-Initiation and Long-Acting Formulation Innovation
  • 4.3 Market Restraints
    • 4.3.1 Stigma and Low Treatment-Seeking
    • 4.3.2 Addiction-Specialist and Prescriber Shortages
    • 4.3.3 Fragmented Reimbursement for Digital and Integrated Care
    • 4.3.4 Relapse, Non-Adherence, and Treatment Discontinuation
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Threat of Substitutes
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Bargaining Power of Suppliers
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Treatment Type
    • 5.1.1 Medication-Assisted Treatment (MAT)
    • 5.1.2 Behavioral Therapy
    • 5.1.3 Counseling & Support Programs
    • 5.1.4 Detoxification Programs
    • 5.1.5 Rehabilitation Programs
  • 5.2 By Addiction Type
    • 5.2.1 Opioid Addiction
    • 5.2.2 Tobacco/Nicotine Addiction
    • 5.2.3 Cannabis Addiction
    • 5.2.4 Prescription Drug Addiction
    • 5.2.5 Stimulant Addiction
    • 5.2.6 Other Addiction Types (Hallucinogens and Ketamine & Club Drug Addiction, Among Others)
  • 5.3 By Treatment Setting
    • 5.3.1 Inpatient Treatment Centers
    • 5.3.2 Residential Rehabilitation Centers
    • 5.3.3 Outpatient Treatment Centers
  • 5.4 By Age Group
    • 5.4.1 Adolescents (12-17 Years)
    • 5.4.2 Adults (18-64 Years)
    • 5.4.3 Geriatric Population (65+ Years)
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
    • 6.3.1 Acadia Healthcare Company, Inc.
    • 6.3.2 Alkermes plc
    • 6.3.3 American Addiction Centers
    • 6.3.4 BayMark Health Services
    • 6.3.5 BHG Holdings, LLC
    • 6.3.6 Braeburn Inc.
    • 6.3.7 Camurus AB
    • 6.3.8 Cipla Limited
    • 6.3.9 Crossroads Treatment Centers
    • 6.3.10 Ethypharm
    • 6.3.11 Hazelden Betty Ford Foundation
    • 6.3.12 Hikma Pharmaceuticals
    • 6.3.13 Indivior PLC
    • 6.3.14 Orexo AB
    • 6.3.15 Pinnacle Treatment Centers
    • 6.3.16 Recovery Centers of America
    • 6.3.17 Rusan Pharma
    • 6.3.18 Teva Pharmaceutical Industries Ltd.
    • 6.3.19 Titan Pharmaceuticals, Inc.
    • 6.3.20 Viatris Inc.

7. Market Opportunities & Future Outlook

  • 7.1 White-space & unmet-need assessment

Global Drug Addiction Treatment Market Report Scope

As per the scope of the report, drug abuse treatment refers to the medical, psychological, and behavioral interventions used to help individuals overcome dependence on drugs and addictive substances. It aims to reduce substance use, manage withdrawal symptoms, prevent relapse, and restore physical and mental well-being.

The drug addiction treatment market is segmented by treatment type, addiction type, age group, treatment setting, and geography. By treatment type, the market includes medication-assisted treatment (MAT), behavioral therapy, counseling and support programs, detoxification programs, and rehabilitation programs. By addiction type, it covers opioid addiction, tobacco/nicotine addiction, cannabis addiction, prescription drug addiction, stimulant addiction, and other substance addictions. By age group, the market includes adolescents (12–17 years), adults (18–64 years), and the geriatric population (65+ years). By treatment setting, it includes inpatient treatment centers, residential rehabilitation centers, and outpatient treatment centers. Geographically, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. Market size and forecasts are provided in terms of value (USD).

Segmentation Overview

By Treatment Type
Drug Addiction Treatment Market segmentation breakdown
Medication-Assisted Treatment (MAT)
Behavioral Therapy
Counseling & Support Programs
Detoxification Programs
Rehabilitation Programs
By Addiction Type
Drug Addiction Treatment Market segmentation breakdown
Opioid Addiction
Tobacco/Nicotine Addiction
Cannabis Addiction
Prescription Drug Addiction
Stimulant Addiction
Other Addiction Types (Hallucinogens and Ketamine & Club Drug Addiction, Among Others)
By Treatment Setting
Drug Addiction Treatment Market segmentation breakdown
Inpatient Treatment Centers
Residential Rehabilitation Centers
Outpatient Treatment Centers
By Age Group
Drug Addiction Treatment Market segmentation breakdown
Adolescents (12-17 Years)
Adults (18-64 Years)
Geriatric Population (65+ Years)
By Geography
Drug Addiction Treatment Market segmentation breakdown
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Drug Addiction Treatment Market segmentation breakdown
By Treatment Type Medication-Assisted Treatment (MAT)
Behavioral Therapy
Counseling & Support Programs
Detoxification Programs
Rehabilitation Programs
By Addiction Type Opioid Addiction
Tobacco/Nicotine Addiction
Cannabis Addiction
Prescription Drug Addiction
Stimulant Addiction
Other Addiction Types (Hallucinogens and Ketamine & Club Drug Addiction, Among Others)
By Treatment Setting Inpatient Treatment Centers
Residential Rehabilitation Centers
Outpatient Treatment Centers
By Age Group Adolescents (12-17 Years)
Adults (18-64 Years)
Geriatric Population (65+ Years)
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

What is the projected value of the drug addiction treatment market by 2032?

The drug addiction treatment market is forecast to reach USD 25.29 billion by 2032, growing at a 7.09% CAGR from 2027 to 2032.

Which treatment type leads drug addiction treatment revenue?

Medication-assisted treatment led with 33.21% revenue share in 2026, while behavioral therapy is forecast to grow fastest at an 8.16% CAGR through 2032.

Why are outpatient addiction treatment centers expanding?

Outpatient centers held 44.56% revenue share in 2026 and are forecast to grow at an 8.23% CAGR because they can combine lower-cost visits with telehealth and in-person services.

What addiction type has the highest growth outlook?

Stimulant addiction is forecast to grow at a 7.87% CAGR through 2032, supported by rising cocaine and methamphetamine detection and the need for behavioral care.

Which region is growing fastest for addiction treatment services?

Asia-Pacific is forecast to grow at an 8.02% CAGR through 2032, supported by high unmet treatment needs and growing public treatment programs.

How does telehealth affect opioid use disorder care?

Permanent federal telehealth rules support remote buprenorphine prescribing, which can extend treatment access to rural and underserved populations.

Page last updated on: